Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

NCT05712356 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.

NCT NCT05712356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05712356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Lead sponsor
Lisata Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2023
Completion date
April 5, 2026
Enrollment
66 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, cholangiocarcinoma, extrahepatic cholangiocarcinoma, gall bladder cancer, gall bladder carcinoma, gallbladder cancer, gallbladder carcinoma, intrahepatic cholangiocarcinoma